The European Healthcare Innovation Leadership Network is focused on advancing European healthcare innovation that addresses unmet needs and ensures patient access to valuable treatments in an era of severe budgetary pressures.
The network brings together public and private sector European healthcare leaders committed to improving patient well-being. Members include public and private sector leaders who represent regulators, health technology assessors (HTA), healthcare budget holders, patient representatives, civil society, and medicine developers. The network is supported by AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, and Johnson & Johnson.
Recently, the network began piloting a new way for diverse stakeholders to engage critical questions about medicines in development, enabling health systems to provide the right medicines to the right patients at the right time. As these pilots move forward, the network will continue to address critical emerging issues in healthcare.
Recent network topics:
The Post-launch Value Assessment Working Group launched in September 2012 bringing together key thought leaders and decision-makers who are committed to developing a more rational and effective decision framework to guide evidence generation after the registration of a new medicine.
Participants launched the Alzheimer's Disease Working Group in Paris in June 2012. The goal of this multi-stakeholder group is to address the need for greater clarity in the development of new approaches to AD.
On 3-4 May 2012, European healthcare leaders convened for the 10th meeting of the European Healthcare Innovation Leadership Network ("the Network") in London. The meeting took place amidst increasing economic and political turbulence. Participants discussed the impact of the political climate on their ability to engage other healthcare leaders to collectively improve health system performance.
Pilots of multi-country, multi-stakeholder consultation in drug development create a new model of engagement to address strategic questions.
In 2009, Tapestry convened type-2 diabetes and breast cancer Working Groups of medical experts, regulators, payers, reimbursement authorities, patients, and the pharmaceutical industry to develop disease-specific value frameworks.
The activities of the Network led to the launch of a new pilot process for multi-country, multi-stakeholder consultations in drug development.
European Healthcare Innovation Leadership Network
President – Europe, Bristol–Myers Squibb